Physician profile
Rosemary Ouseph
NPI 1740261783
$3,448.43
in general payments reported to CMS, 2019-2025
16 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $544 · 2022: $594 · 2023: $531 · 2024: $932 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $487.09 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $365.39 | 2023-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $351.55 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $338.37 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $241.56 | 2021-2025 | |
| Scpharmaceuticals INC. | $238.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.46 | 2023-2024 | Livtencity |
| Baxter Healthcare | $220.89 | 2021-2024 | Renal - Acute |
| Travere Therapeutics, INC. | $217.96 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $133.01 | 2023-2024 | Prevymis |
| Mallinckrodt Enterprises LLC | $124.59 | 2019 | |
| Abbvie INC. | $122.41 | 2025 | |
| Nxstage Medical, INC. | $119.85 | 2021-2023 | Nxstage Cartridge Express, Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $119.70 | 2024 | Farxiga |
| Genzyme Corporation | $113.40 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Ouseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.